CR20110034A - Peptidos de señalizacion de la crkl - Google Patents

Peptidos de señalizacion de la crkl

Info

Publication number
CR20110034A
CR20110034A CR20110034A CR20110034A CR20110034A CR 20110034 A CR20110034 A CR 20110034A CR 20110034 A CR20110034 A CR 20110034A CR 20110034 A CR20110034 A CR 20110034A CR 20110034 A CR20110034 A CR 20110034A
Authority
CR
Costa Rica
Prior art keywords
crkl
signaling peptides
peptides
signaling
signal
Prior art date
Application number
CR20110034A
Other languages
English (en)
Inventor
Arap Wadih
J Mintz Paul
Pasqualini Renata
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CR20110034A publication Critical patent/CR20110034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan métodos y composiciones para señalizar selectivamente la CRKL a través del uso de péptidos de señalización.
CR20110034A 2008-06-20 2011-01-20 Peptidos de señalizacion de la crkl CR20110034A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7442308P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
CR20110034A true CR20110034A (es) 2011-06-24

Family

ID=41434721

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110034A CR20110034A (es) 2008-06-20 2011-01-20 Peptidos de señalizacion de la crkl

Country Status (14)

Country Link
US (1) US20110189095A1 (es)
EP (1) EP2303913A4 (es)
JP (1) JP2011525491A (es)
CN (1) CN102105487A (es)
BR (1) BRPI0915718A2 (es)
CA (1) CA2728763A1 (es)
CL (1) CL2010001498A1 (es)
CO (1) CO6331291A2 (es)
CR (1) CR20110034A (es)
EC (1) ECSP10010729A (es)
IL (1) IL210053A0 (es)
MX (1) MX2010014173A (es)
PE (1) PE20110309A1 (es)
WO (1) WO2009155556A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101870734B (zh) * 2010-05-25 2012-06-20 北京大学 一种抑制新生血管生成的融合多肽及其编码基因与应用
CU23950B1 (es) * 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología Péptidos cíclicos con actividad antineoplásica y antiangiogénica
PE20160991A1 (es) * 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CN105612174A (zh) * 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的二硫化物环状多肽
CN105612172A (zh) * 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
CN104250287B (zh) 2013-09-11 2017-03-22 中山大学附属肿瘤医院 肿瘤靶向多肽及应用
US10130650B2 (en) 2014-01-27 2018-11-20 The Children's Hospital Of Philadelphia Compositions and methods for treating autoimmune and inflammatory diseases
CN108303539B (zh) * 2018-01-31 2020-08-11 刘双萍 一种乳腺癌细胞检测生物试剂及应用
CN110025577B (zh) * 2019-03-19 2021-09-07 广东药科大学 一种多肽药物口服靶向系统M27-39@FA-MCNs复合体及其制备方法和应用
CN109908369B (zh) * 2019-04-28 2022-02-11 复旦大学附属金山医院 一种新的环状RNA circCRKL在前列腺癌治疗中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667981A (en) * 1994-05-13 1997-09-16 Childrens Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2004020999A1 (en) * 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP1824796A4 (en) * 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
US20120017338A1 (en) * 2008-01-15 2012-01-19 Wei Wu Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plant with enhanced agronomic traits

Also Published As

Publication number Publication date
CO6331291A2 (es) 2011-10-20
EP2303913A4 (en) 2013-07-24
ECSP10010729A (es) 2011-04-29
IL210053A0 (en) 2011-02-28
JP2011525491A (ja) 2011-09-22
WO2009155556A3 (en) 2010-04-08
US20110189095A1 (en) 2011-08-04
CN102105487A (zh) 2011-06-22
BRPI0915718A2 (pt) 2017-06-20
CA2728763A1 (en) 2009-12-23
CL2010001498A1 (es) 2011-05-20
EP2303913A2 (en) 2011-04-06
WO2009155556A2 (en) 2009-12-23
PE20110309A1 (es) 2011-06-19
MX2010014173A (es) 2011-06-20

Similar Documents

Publication Publication Date Title
CR20110034A (es) Peptidos de señalizacion de la crkl
ECSP11011557A (es) Mimético de smac
ECSP11010814A (es) Derivados de ciclohexil-amida y su uso como antagonistas de los receptores de crf-1
CR20140180A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
PA8836801A1 (es) Polipeptidos g-csf de bovino modificados y sus usos
CL2009001263S1 (es) Maquina de afeitar.
ECSP12012011A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
UY34306A (es) Pirimidinas condensadas sustituidas y su uso
DE602007012072D1 (de) Orantagonisten
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
MA34025B1 (fr) Polypeptides se liant au bêta-a
BRPI1012728A2 (pt) uso de tripeptídeos
CR20110576A (es) Anticuerpos anti-egfl7 humanizados y métodos de uso de los mismos
CU20130057A7 (es) Polipéptidos del factor ix modificados y usos de los mismos
BRPI1014914A2 (pt) Composição contendo trehalulose, sua preparação e uso
HN2011000076A (es) Derivados de piridino-piridinonas, su preparacion.
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
DK3311666T3 (da) Diketoner og hydroxyketoner som aktivatorer af catenin-signalvejen
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
UY30801A1 (es) Compuestos calciliticos
CL2008001014A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol.